


In the claims:

1. **(Currently Amended)** A compound of formula (I):



(I)

wherein:

R<sup>1</sup> is H, CH<sub>2</sub>R<sup>5</sup> or COR<sup>6</sup>;

R<sup>2</sup> is alkyl C<sub>1-6</sub> or alkenyl C<sub>1-6</sub>, optionally substituted by one or more groups selected from alkyl C<sub>1-6</sub> and halogen;

R<sup>3</sup> is cycloalkyl C<sub>3-8</sub>, optionally substituted by R<sup>7</sup>;

R<sup>4</sup> is H or alkyl C<sub>1-6</sub>, optionally substituted by one or more halogens;

R<sup>5</sup> is H, phenyl or alkyl C<sub>1-6</sub>, optionally substituted by halogen, OR<sup>8</sup>, and phenyl;


R<sup>6</sup> is OR<sup>9</sup> or alkyl C<sub>1-6</sub>, optionally substituted by one or more groups selected from halogen, OR<sup>10</sup>, and phenyl;

R<sup>7</sup> is phenyl, optionally substituted by one or more groups selected from alkyl C<sub>1-6</sub>, halogen, and OR<sup>8</sup>;

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup>, are independently H or alkyl C<sub>1-6</sub>, optionally substituted by one or more groups selected from halogen or alkyl C<sub>1-6</sub>;

or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.


2. **(Previously Presented)** A compound of according to claim 1 which is:



(Ia)

where  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are as defined in claim 1.

3. **(Currently Amended)** A compound according to claim 1 or 2 in which  $R^3$  is  
wherein:



$R^7$  is phenyl, optionally substituted by one or more groups selected from alkyl  $C_{1-6}$ , halogen, and  $OR^8$ ;

$R^8$  is independently H or alkyl  $C_{1-6}$ , optionally substituted by one or more groups selected from halogen or alkyl  $C_{1-6}$ .

~~where  $R^7$  is as defined in claim 1.~~

4. **(Currently Amended)** A compound according to ~~any one of~~ claims 1 or 2 ~~to 3~~ in which  $R^1$  is H,  $CH_2Ph$ ,  $CH_2CH_2OH$ , or  $CO_2tBu$ .

5. **(Currently Amended)** A compound according to ~~any one of~~ claims 1 or 2 ~~to 4~~ in which  $R^2$  is n-Pr.

6. **(Currently Amended)** A compound according to ~~any one of~~ claims 1 or 2 ~~to 5~~ in which R<sup>3</sup> is cycloalkyl C<sub>3-8</sub> substituted by phenyl.

7. **(Currently Amended)** A compound according to ~~any one of~~ claims 1 or 2 ~~to 6~~ in which R<sup>4</sup> is H or methyl.

8. **(Currently Amended)** A compound according to claim 1 which is:

[3*R*-[3 $\alpha$ ,4 $\beta$ (1*R*\*,2*S*\*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*S*-[3 $\alpha$ ,4 $\beta$ (1*S*\*,2*R*\*)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;

[3*S*-[3 $\alpha$ ,4 $\beta$ (1*R*\*, 2*S*\*)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;

[3*S*-[3 $\alpha$ ,4 $\beta$ (1*S*\*,2*R*\*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*R*-[3 $\alpha$ ,4 $\beta$ (1*R*\*,2*S*\*)]]-4-[7-[*N*-Methyl-*N*-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*R*-[3 $\alpha$ ,4 $\beta$ (1*R*\*,2*S*\*)]]-1-Hydroxyethyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*R*-[3 $\alpha$ ,4 $\beta$ (1*R*\*,2*S*\*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-(phenylmethyl)-3-pyrrolidinol;

[3*R*-[3 $\alpha$ , 4 $\beta$ (1*R*\*,2*S*\*)]]-1-Acetyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;-

~~or~~ ~~or~~ a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.

9. **(Previously Presented)** A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 in combination with a pharmaceutically acceptable diluent, adjuvant or carrier.

10 - 12. **(Cancelled)**

13. **(Currently Amended)** A compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~ for use in the treatment ~~or prevention~~ of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease.

14. **(Currently Amended)** A compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~ for use in the treatment ~~or prevention~~ of unstable or stable angina.

15. **(Currently Amended)** A compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~ as an active ingredient in the manufacture of a medicament for use in the treatment ~~or prevention~~ of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease.

16. **(Currently Amended)** A compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~ as an active ingredient in the manufacture of a medicament for use in the treatment ~~or prevention~~ of unstable or stable angina


17. **(Currently Amended)** A method of treatment ~~or prevention~~ of a platelet aggregation disorder which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~.

18. **(Currently Amended)** A method of treatment ~~or prevention~~ of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease, which

comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of a compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~.

19. **(Currently Amended)** A method of treatment ~~or prevention~~ of unstable or stable angina, which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of a compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~.


20. **(Previously Presented)** A process for the preparation of a compound of formula (I), where  $R^1$  is H, which comprises reacting a compound of formula (II)




(II)

wherein  $R^2$  is as defined in claim 1 and  $P$  is a protecting group, with  $R^3R^4NH$ , wherein  $R^3$  and  $R^4$  are as defined in claim 1, and a base and optionally thereafter removing any protecting groups.


21. **(Withdrawn from Consideration)** Compounds of formula (II), (III), (IV) and (V)




(II)



(III)



(IV)



(V)

wherein R<sup>2</sup> is as defined in claim 1 and P is a protecting group.